News articles about Haemonetics (NYSE:HAE) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Haemonetics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 46.5624758590241 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Haemonetics (HAE) Cut to Hold at Zacks Investment Research (americanbankingnews.com)
- Haemonetics Corporation (HAE) to Post Q3 2018 Earnings of $0.45 Per Share, Jefferies Group Forecasts (americanbankingnews.com)
- Validant Names Brian Burns as CEO (kait8.com)
- Haemonetics Corporation (HAE) to Post FY2019 Earnings of $2.00 Per Share, Jefferies Group Forecasts (americanbankingnews.com)
- Haemonetics (HAE) Rating Increased to Buy at Zacks Investment Research (americanbankingnews.com)
A number of research firms have commented on HAE. Zacks Investment Research cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Wednesday. Craig Hallum reissued a “hold” rating and issued a $50.00 price target (up previously from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. Barrington Research boosted their price target on shares of Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Jefferies Group boosted their price target on shares of Haemonetics from $18.00 to $75.00 and gave the stock a “buy” rating in a research note on Monday, January 8th. Finally, Raymond James Financial raised shares of Haemonetics from an “underperform” rating to a “market perform” rating in a research note on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. Haemonetics has an average rating of “Hold” and a consensus target price of $58.83.
Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.07. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. The company had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. During the same quarter in the prior year, the company earned $0.38 EPS. The firm’s revenue was up 2.3% on a year-over-year basis. analysts predict that Haemonetics will post 1.69 earnings per share for the current year.
In other news, CFO Willaim P. Burke sold 13,193 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $54.04, for a total value of $712,949.72. Following the completion of the sale, the chief financial officer now owns 27,227 shares of the company’s stock, valued at approximately $1,471,347.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Dan Goldstein sold 4,691 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $54.93, for a total transaction of $257,676.63. Following the completion of the sale, the chief accounting officer now directly owns 3,747 shares of the company’s stock, valued at approximately $205,822.71. The disclosure for this sale can be found here. Insiders sold a total of 54,486 shares of company stock valued at $3,050,827 in the last ninety days. 1.20% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Haemonetics (HAE) Given Coverage Optimism Rating of 0.20” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2018/01/14/haemonetics-hae-given-coverage-optimism-rating-of-0-20.html.
Haemonetics Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
What are top analysts saying about Haemonetics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Haemonetics and related companies.